Bone marrow-derived mesenchymal stem cells (MSCs) are known to interact with hematopoietic stem cells (HSCs) and immune cells, and represent potential cellular therapy to enhance allogeneic hematopoietic engraftment and prevent graft-versus-host disease (GVHD). We investigated the role of human MSCs in NOD-SCID mice repopulation by unrelated human hematopoietic cells and studied the immune interactions between human MSCs and unrelated donor blood cells in vitro. When hematopoietic stem cell numbers were limited, human engraftment of NOD-SCID mice was observed only after coinfusion of unrelated human MSCs, but not with coinfusion of mouse mesenchymal cell line. Unrelated human MSCs did not elicit T-cell activation in vitro and suppressed T-cell activation by Tuberculin and unrelated allogeneic lymphocytes in a dose-dependent manner. Cellfree MSC culture supernatant, mouse stromal cells and human dermal fibroblasts did not elicit this effect. These preclinical data suggest that unrelated, human bone marrow-derived, culture-expanded MSCs may improve the outcome of allogeneic transplantation by promoting hematopoietic engraftment and limiting GVHD and their therapeutic potential should be tested in clinic.
munosuppression
Graft failure and graft-versus-host disease (GVHD) remain significant obstacles to a successful outcome in allogeneic hematopoietic stem cell transplantation. There is a growing interest in cotransplantation of allogeneic stromal and hematopoietic progenitors to improve the patient outcome after allogeneic transplantation. 1 Here we investigated the interaction between bone marrow-derived mesenchymal stem cells (MSC) and the hematopoietic stem cells to determine if MSCs could support allogeneic hematopoietic stem cell transplantation by facilitating engraftment without increasing the risk of GVHD. Several groups have described nonhematopoietic, plastic-adherent progenitor cells derived from adult human bone marrow aspirates, which are capable of differentiating into mature mesenchymal cells. [2] [3] [4] [5] [6] It is thought that these progenitors give rise to adventitial and other mesenchymal cells in the marrow that fabricate the connective tissue scaffolding, and produce cytokines, chemokines and extracellular matrix proteins that regulate hematopoietic homing and proliferation.
7-10 Therefore, we hypothesized that MSCs could support the survival of hematopoietic stem cells and tested this using an in vivo model of human hematopoietic stem cell engraftment and survival using NOD-SCID mice.
Furthermore, several groups have recently shown that MSCs suppress T-lymphocyte proliferation in response to allogeneic stimuli. [11] [12] [13] [14] This suppressive effect of MSCs appears to be partially mediated by soluble factors, although there are conflicting data. Therefore, we investigated the immune interactions between MSCs and unrelated allogeneic lymphocytes in vitro using Elispot assay.
In experiments described here, we used a human bone marrow-derived population of adherent cells described by Haynesworth et al 3 that have extensive proliferative capacity and ability to differentiate along the osteogenic, chondrogenic and adipogenic lineages both in vitro and in vivo. 15 In unstimulated cultures, MSCs appear as fusiform fibroblasts with the expression of unique surface proteins (recognized by monoclonal antibodies SH2 and SH3) 16 not found on hematopoietic precursors. We have previously demonstrated the feasibility of culturing large numbers of these cells ex vivo and safety of their intravenous infusion into patients. 17, 18 Therefore, our results are directly relevant to acceptable cellular therapy that can be tested in clinic. In this manuscript, we show that coinfusion of human MSCs and unrelated umbilical cord blood (UCB) cells into NOD-SCID mice results in improved frequency and degree of human engraftment when UCB dose is limiting. We also found that allogeneic-unrelated MSCs do not elicit T-cell activation in vitro. On the contrary, unrelated donor MSCs inhibited T-cell activation normally seen in mixed lympho-cyte reactions. This effect could not be elucidated with MSC culture supernatant alone.
Materials and methods

Mesenchymal stem cell procurement
Human MSC cultures were established as described previously. 17 Briefly, bone marrow was aspirated (10-30 ml) under local anesthesia from healthy volunteer donors after consent approved by the IRB of the University Hospitals of Cleveland. Mononuclear cells (MNCs) were isolated by Percoll (d 1.073 gm/ml, Sigma, St Louis, MO, USA) gradient centrifugation and plated at a density of 1 Â 10 6 cells per ml in 175 cm 2 polystyrene flasks (Falcon, Beckton Dickinson Comp. Franklin Lakes, NJ, USA) in Dulbecco's minimum essential medium (DMEM) with a selected batch of 10% fetal bovine serum (FBS) (Hyclone, Logan, UT, USA). Cells were allowed to adhere for 72 h followed by the removal of nonadherent cells and media changes every 3-4 days. Adherent cells were removed with 0.05% trypsin-EDTA (Gibco) and replated (passaged) at a density of 1 Â 10 6 per 175 cm 2 . Multiple individual donor preparations were performed and second or third passage MSCs were used for individual experiments. All MSC preparations were morphologically identical and uniformly expressed SH2 and SH3 markers as described previously. 17 
Dermal fibroblasts
Papillary dermal fibroblasts were a generous gift from Dr IA Schafer. Cells were prepared by dermatoming skin at a depth of about 0.3 mm. The epidermal sheet was removed and the remaining dermal component was cut into small pieces and placed onto the surface of a plastic culture dish and covered with culture medium as described. 19 High passage cells, devoid of contaminating keratinocytes and vascular endothelial cells, were used in experiments.
BMC9 mesenchymal progenitor cell line
A conditionally immortalized marrow-derived mesenchymal cell clone, BMC9, was isolated from a transgenic mouse (H-2Kb-tsA58) containing a gene for conditional immortality as previously described. 20 This cell line exhibits mesenchymal cell phenotypes, chondrocyte, adipocyte, stromal and osteoblast and supports LTC-ICs out to 5 weeks (unpublished data). The expression of large Tantigen does not impede the inherent hematopoietic support capabilities of these cells. Nor does large T-antigen expression artificially promote hematopoietic support as other clones of marrow cells show no LTC-IC support.
Umbilical cord blood cells
Human UCB was collected into sterile bags containing citrate dextrose after the delivery of full-term neonates from healthy volunteer mothers. This procedure was approved by the IRB of the University Hospitals of Cleveland. Red cells were sedimented using 6% dextran and MNCs were isolated using a density gradient centrifugation. All cells were used fresh, without cryopreservation.
NOD-SCID mice infusion and detection of human engraftment
Human hematopoietic engraftment was evaluated in irradiated NOD-SCID mice after infusing human UCB cells with or without coinfusion of allogeneic human MSCs. Recipient 6-8-week-old NOD-SCID mice were given sublethal total body irradiation (250 cGy) 24 h prior to infusion using a cesium source. Cohorts of 4-8 mice were injected intravenously with UCB cells at doses of 2 to 8 Â 10 6 per mouse, alone or mixed with 1 Â 10 6 human MSCs (unrelated donor to UCB cells) or 1 Â 10 6 conditionally immortalized mouse mesenchymal progenitor cells (clone BMC9). 20 Mice were kept in microisolator cages and fed irradiated food and water containing penicillin. Mice were killed 6-7 weeks after cell infusion and long bones of hind legs were extracted. Bone marrow cells were flushed into medium and used for flow cytometry or plated for growth of human MSCs as described above. Human cell engraftment was detected by flow cytometry, using anti-human CD45 antibody conjugated to PE (Pharmingen, San Diego, CA, USA) and isotype control antibody, Mouse IgG1-PE (Becton Dickinson, Parsippany, NJ, USA). Percent human engraftment was calculated after subtraction of the background detected in control mice and 0.5% was designated as the lower threshold for unequivocal human engraftment.
Interferon-g Elispot assay
ELISPOT plates (96-well) (Polyfiltronics, Rockland MA, USA) were coated with capture antibody for human interferon-gamma (2G1, Endogen, Woburn, MA, USA) as described elsewhere. 21 In total, 150 000 responder peripheral blood MNCs were added to each well in 100 ml of medium. The cells were activated in vitro with phytohemaglutinin (PHA 10 mg/ml final concentration; Sigma, St Louis, MO, USA) or unrelated (non-HLAmatched) allogeneic cells. After 24 h, the plates were washed and biotinlated detection antibody (B133.5, Endogen, 4 mg/ml) was added to the wells overnight at 41C. Strepavidin-HPR (Dako, Carpenteria, CA, USA) was then added for 2 h at room temperature. The spots were developed using 3-amino-9-ethylcarbazole (Pierce, Rockford, IL, USA). The resulting spots were counted on a computer-assisted ELISPOT image analyzer Immunospot (Cellular Technology, Cleveland, OH, USA).
MSC culture-conditioned medium preparation
Culture-conditioned medium consisted of MSC culture medium (DMEM with selected batch of 10% FBS) placed over 70-80% confluent human MSCs for 24-48 h. Supernatant was obtained and filtered twice using 0.2 mm filters to exclude cells. In some experiments, the medium was conditioned over a mixture of MSCs and unrelated donor peripheral blood lymphocytes.
Statistical analysis
The results are expressed as mean7s.e.m. Differences between experimental conditions were analyzed by t test (paired when possible). A P-value of less than 0.05 was considered statistically significant.
Results
Human CD45 þ cell engraftment in NOD-SCID mice To determine whether human MSCs supported engraftment and survival of human hematopoietic stem cells in vivo, we infused 2, 4 or 8 Â 10 6 human UCB MNCs with or without 1 Â 10 6 unrelated human MSCs into sublethally irradiated NOD-SCID mice. In mice receiving UCB cells alone, high levels of human engraftment were seen with 8 Â 10 6 UCB cell dose (Figure 1 ), whereas no engraftment was seen after infusion of 2 Â 10 6 UCB cell dose. Only two out of 10 mice had detectable (40.5%), but low levels (o1%) of human engraftment after infusion of 4 Â 10 6 UCB cells. In contrast, eight out of 10 mice had human engraftment after coinfusion of 4 Â 10 6 UCB cells plus 1 Â 10 6 unrelated human MSCs (P ¼ 0.02 by Fisher's exact test) (Figure 2) . None of the four mice had human engraftment after coinfusion of 4 Â 10 6 UCB cells plus 1 Â 10 6 immortalized mouse mesenchymal cells (BMC-9 line). This was not statistically significantly different compared to the mice given 4 Â 10 6 UCB cells alone. Furthermore, the level of human engraftment was also significantly higher in mice coinfused with human MSCs (2.572 vs 0.270.2%, two-tailed P ¼ 0.005, unpaired t test with Welch correction) compared to UCB alone ( Figure 3 ).
Immune suppression of human MSCs
Human-Interferon-g Elispot assay was used to determine if human MSCs activated T-cells in unrelated human blood. Elispot is a highly sensitive assay (limit of detection 5 reactive lymphocytes out of 300 000) that is capable of characterizing the frequencies of alloantigen-specific T cells in short-term culture. Three pairs of MSCs and peripheral blood MNCs derived from six different random adult donors were tested, and we did not detect activated T-cell clones above the background in any pair (Figure 4 ). Same MNCs gave a high number of spots in mixed lymphocyte cultures and when stimulated with PHA (positive controls). Reactivity against unrelated, allogeneic MSCs was not observed at 1 : 4, 1 : 1 and 4 : 1 target effector ratios (data not shown). Next, the impact of unrelated human MSCs on an ongoing mixed lymphocyte reaction was evaluated. In three independent experiments, a significant reduction of spot formation occurred in the presence of MSCs ( Figure 5 ). This suppression was also observed when the activation of T-lymphocytes in the mixed lymphocyte reaction was enhanced by the addition of human interleukin-2 to the wells. To determine if this inhibition of Tcell activation could be achieved by humoral factors secreted by the MSCs, Elispot reaction was performed in a cell-free culture supernatant of MSCs (Figure 6a) . In contrast to the inhibitory effect of MSCs, the MSC supernatant failed to inhibit T-cell activation, and, on the contrary, MSC supernatant had a stimulatory effect on Peripheral blood lymphocytes (150 000/well) from two unrelated donors (L1 and L2) were mixed in EliSpot plates with or without human interleukin-2 (IL2, 10 U/well). There was a significant reduction in activated lymphocytes by addition of 150 000 human MSCs (donor unrelated to either blood donors) both in the absence (*: P ¼ 0.002) and presence of human IL-2 (y: P ¼ 0.009). Data from three independent experiments with triplicate wells in each condition. mixed lymphocyte cultures. Surprisingly, the cell-free supernatant obtained from a mixture of MSCs and unrelated lymphocytes had an inhibitory effect similar to that seen with the addition of MSCs (Figure 6b ). To determine if MSCs could also suppress Tuberculin purified protein derivative (PPD, Evans Medical Lim. Horsham, England)-induced T-cell activation, peripheral MNCs of a PPD skin test positive individual were incubated with PPD. The addition of unrelated MSCs to this reaction decreased the number of PPD-stimulated lymphocytes in a dose-dependent manner (Figure 7) . To determine the specificity of MSC-mediated suppression of T-cell activation, rat MSCs, human dermal fibroblasts and murine NIH3T3 cells were also tested in the same assay system. While unrelated human MSCs and xenogeneic rat MSCs did not elicit human T-cell activation, unrelated human dermal fibroblasts and murine NIH-3T3 cells elicited T-cell activation (Figure 8) . Furthermore, human dermal fibroblasts failed to suppress the mixed lymphocyte reaction. Peripheral blood lymphocytes (150 000/well) from 2 unrelated donors (L1 and L2) were mixed in EliSpot plates with rat MSCs, human MSCs, murine fibroblast cell line NIH-3T3 or human dermal fibroblasts. Both rat and unrelated human MSCs failed to activate lymphocytes, while NIH-3T3 cells activated them. Mixed lymphocyte reaction (L1 þ L2) was inhibited by human MSCs but not by human dermal fibroblasts.
transplanted with a single unit unrelated UCB, engraftment failure is approximately 10-15% and hematopoietic recovery is delayed. 22 This is likely due to the limiting numbers of hematopoietic stem cells found in a single unit of UCB compared to conventional allogeneic graft sources. Thus, our data suggest that coinfusion of MSCs in adult patients undergoing a single donor UCB transplantation may improve engraftment rate and kinetics. Similar to the clinical situation, we did not have access to UCB donor MSCs and were forced to use unrelated MSCs. Our in vitro studies show that unrelated MSCs were not immunogenic, but rather immunosuppressive and suggest that therapeutic MSCs may be obtained from donors unrelated to the UCB donor in support of UCB transplantation.
A number of preclinical animal models of stromal cell transplantation have been established to support hematopoietic engraftment. 23, 24 Both autologous and allogeneic human marrow stromal cells were shown to improve the quantity and duration of human hematopoietic engraftment in a preimmune sheep model. 25 Although stromal cells used in these experiments contained a mixture of STRO-1 þ cells, macrophages, CD8 þ cells and rare CD34 þ cells, the effect on human hematopoiesis was thought to be mediated by the STRO-1 þ stromal precursor cells. Noort et al 26 reported that human fetal lung-derived MSCs promoted human UCB engraftment in NOD-SCID mice. Similar to our findings, human engraftment was enhanced only when transplanted UCB CD34 þ cell numbers were limited at 0.03-0.1 Â 10 6 /mouse. In contrast to adult bone marrow-derived MSCs, the clinical use of human fetal lung-derived MSCs may be more difficult due to the limited availability of such tissues and ethical concerns with procurement. Angelopoulou et al 27 recently reported that cotransplantation of human MSCs enhanced myelopoiesis and megakaryopoiesis in NOD-SCID mice transplanted with the limiting doses of peripheral blood CD34 þ cells. Our results extend these observations to umbilical cord blood cells and suggest an important supportive role for MSCs in the pre-clinical models of hematopoietic transplantation.
The mechanism of human hematopoietic support in NOD-SCID mice by human MSCs is not clear at this time. Noort et al 26 did not find any impact of fetal lung MSCs on the homing of a coinfused CD34 þ cell. It is possible that coinfused MSCs provide secreted human cytokines and hematopoietic niches to support human cells by direct contact. We have previously determined the wide distribution of human MSCs in NOD-SCID mice, particularly to bone marrow and persistence of these cells in vivo over 8 weeks. 28 Evidence of low-level bone marrow engraftment of MSCs was also found in dogs and nonhuman primates after intravenous infusion. 29, 30 We cannot exclude the possibility that the major role of MSCs during cotransplantation is mediated by secreted proteins that have systemic effects and the exact location of MSC engraftment or entrapment may not be relevant.
Using a sensitive Elispot assay, we found that human MSCs did not activate alloreactive peripheral blood cells of unrelated donors. In the same assay system, unrelated donor dermal fibroblasts and xenogeneic mouse fibroblast cell line activated human peripheral blood cells, whereas xenogeneic rat MSCs failed to activate them. Surprisingly, addition of third-party MSCs (unrelated to either peripheral blood donors) to a mixed lymphocyte reaction demonstrated an inhibitory effect. This inhibition was even more evident when the reaction was enhanced with supplemental human IL-2. This effect did not appear to be specific to alloantigens since Tuberculin activation of T-lymphocytes was also inhibited in the presence of MSCs. This is the first use of Elispot assay, investigating the interaction between MSCs and immune cells.
Our results suggest that human MSCs directly inhibit the activation of alloreactive T-lymphocytes and this effect may have important therapeutic implications in the setting of transplantation across HLA barriers and GVHD.
DiNicola et al 13 reported that human bone marrow stromal cells suppress T-lymphocyte proliferation in vitro. The mechanism of this suppression appeared to be mediated by soluble factors, including hepatocyte growth factor and transforming growth factor-b. In these experiments, monocyte-macrophage depleted long-term bone marrow culture-derived stromal cells were used. Since these cultures are heterogenous in nature, it is difficult to determine the cell population contributing to the observed effect. Our results suggest that the homogenous population of MSCs may be the predominant effector cells of stromal cultures. In contrast to the findings of DiNicola et al, we did not find MSC culture supernatant to have a T-cell inhibitory effect. On the contrary, the addition of MSC conditioned medium to mixed lymphocytes enhanced the lymphocyte activation. However, when we used conditioned medium obtained from a mixture of MSCs and unrelated lymphocytes, we observed a significant inhibition of the mixed lymphocyte activation. This finding suggests that MSC-lymphocyte interaction results in the release of substances (transferable in medium) either from MSCs or lymphocytes that have a direct inhibitory effect. We are currently investigating the nature of this substance and its source. Tse et al 12 also found MSCs to suppress mixed lymphocyte proliferation; however, this did not appear to be mediated by IL-10, TGF-b1, prostaglandin E2 secretion or tryptophan depletion. Le Blanc et al 11 have reported that MSCs suppress T-cell proliferation both by allogeneic antigens and mitogens such as PHA and concanavalin A, suggesting a nonspecific antiproliferative effect. More recently, Krampera et al 31 found that mouse bone marrow-derived adherent cells inhibit naı¨ve and memory antigen-specific T cells using HY peptide-stimulated splenocytes from transgenic HY-TCRhigh mice. This inhibition was contact dependent and not dependent on APC or CD4 þ /CD25 þ cells. Further research is needed to understand the mechanism of the inhibitory actions of MSCs on T-lymphocytes.
There is also evidence for in vivo immuosuppression by MSCs. Using a baboon skin graft model, Bartholomew et al 14 showed that infusion of ex vivo-expanded donor (baboon) MSCs at a dose of 20 Â 10 6 MSC/kg recipient weight prolonged time to rejection of histoincompatible skin grafts. Even 'third-party' baboon MSCs, obtained from neither recipient nor skin graft donor, appeared to suppress alloreactivity in vivo. These data suggest that immunologic effects of MSCs observed in vitro may also be operative in vivo. Since we used an immunodeficient mice model in our cotransplantation experiments, we were unable to determine the immunosuppressive effects of MSCs on the prevention of hematopoietic stem cell rejection in the setting of xenotransplantation. It is possible that MSC cotransplantation supports allogeneic hematopoiesis in vivo, both by direct hematopoietic survival signals and by inhibition of alloreactive lymphocytes that may lead to rejection.
In conclusion, our data indicate that human MSCs may have a significant therapeutic potential in the setting of allogeneic transplantation by improving the engraftment rate and kinetics and inhibiting T-cell alloreactivity. This effect may be particularly pronounced in the setting of limited donor stem cells such as UCB transplantation and in situations with a high risk of rejection, such as nonmyeloablative preparative regimens and T-cell-depleted transplants across MHC barriers. Furthermore, T-cell-suppressive properties of MSCs may prove useful in preventing or treating acute and chronic GVHD. Hematopoietic support and immunomodulatory effects of MSCs should be further characterized in clinical trials.
